Ask AI
PIK3CA/AKT1/PTEN in Breast Cancer

CE / CME

PIK3CA/AKT1/PTEN Alterations Testing and Management of Patients With Locally Advanced or Metastatic Breast Cancer

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

European Learners: 0.50 EBAC® CE Credit

Released: January 08, 2026

Expiration: July 07, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

What specific biomarker/genetic alteration is required to determine a patient's eligibility for treatment with inavolisib for a patient with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced or metastatic breast cancer?